ONCOLOGY REPORTS 31: 1961-1967, 2014

Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer MING LI1, QIAN ZHANG2, LIANG WU3, CHENGYOU JIA4, FUHUA SHI5, SHAOCAI LI6, AIMEI PENG1, GUOLIANG ZHANG1, XIAOLIAN SONG1 and CHANGHUI WANG1 1

2

Department of Respiratory Medicine, Shanghai 10th People's Hospital, Tongji University, Shanghai 200072; Department of Nephrology, Huashan Hospital, Fudan University, Shanghai 200032; 3Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433; 4Department of Nuclear Medicine, Shanghai 10th People's Hospital, Tongji University, Shanghai 200072; Departments of 5Neural Medicine and 6Cardiology, People's Hospital of Zunhua County, Tangshan, Hebei 064200, P.R. China Received December 16, 2013; Accepted January 27, 2014 DOI: 10.3892/or.2014.3029

Abstract. The aim of the present study was to determine whether serum miR-499 may be used as a biomarker for early detection of non-small cell lung cancer (NSCLC). The present study was designed as an initial screening phase and a subsequent validation phase. In the screening phase, we analyzed serum levels of miR-499 in a subset of 40 patients with stage I (n=20) and stage IV (n=20) NSCLC. In the validation phase, miR-499 expression levels in serum (n=514) and tissue (n=136) from NSCLC patients were detected in a large and independent cohort of 514 patients. miR-499 in the screening phase was found to be significantly elevated in the serum of stage I NSCLC patients compared with that in stage IV NSCLC patients (P

Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer.

The aim of the present study was to determine whether serum miR-499 may be used as a biomarker for early detection of non-small cell lung cancer (NSCL...
473KB Sizes 0 Downloads 2 Views